NEW YORK (GenomeWeb) – NeoGenomics today reported a 26 percent year-over-year increase in first quarter revenues, including a 14 percent rise in testing revenue. 

For the three months ended March 31, the Ft. Myers, Fla.-based cancer genetics testing company posted $23 million in revenues, up from $18.2 million in the year-ago quarter. During the recently completed quarter, NeoGenomics performed 49,396 tests for $20.7 million in testing revenues, compared to 38,734 million tests and $18.2 million in testing revenues in the year-ago period. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.